How Aggressive Breast Cancer Wires Itself Into the Nervous System — and a Drug That Might Cut the Cord

Aggressive breast tumours may do something unsettling: recruit the body’s own nerves to help them grow. Research maps how, and points to a drug already on the market that might interrupt it.

Scientists at the University of Oklahoma, led by Dr Maureen Cox, found that triple-negative breast cancer recruits immune cells called macrophages to release BDNF (brain-derived neurotrophic factor). That signal draws extensive nerve networks into the tumour. The findings were published in Cell Death & Differentiation.

The indirect mechanism is the interesting part

Note what the tumour is not doing. It does not produce the nerve growth signal itself — it recruits macrophages and gets them to produce it.

That indirection recurs throughout cancer biology and is easy to underestimate. Tumours are not simply masses of malignant cells; they are ecosystems that co-opt normal cell types into supporting roles. Macrophages are supposed to be immune defenders, and tumours routinely reprogramme them into suppliers of growth factors, matrix remodelling and immune suppression.

Using them to attract nerves adds a role to that list — and it means blocking the tumour’s own signalling would not have addressed it, because the tumour was never the source.

Why nerves help a tumour

Nerves growing into a tumour may stimulate formation of new blood vessels feeding it oxygen and nutrients, provide a path for cancer cells to migrate during metastasis, and dampen the immune system’s attack.

The migration route is the most concrete. Cancer cells spreading along nerve sheaths — perineural invasion — is a recognised and well-documented phenomenon associated with worse outcomes in several cancers. A nerve entering a tumour is a highway leading out of it.

The vascular effect matters because tumour growth is limited by blood supply, and nerves influence vessel formation and tone. And the immune effect connects to a broader recognition that nerves regulate immune activity in tissue, so a tumour that recruits nerves may be recruiting immune suppression along with them.

The human correlation

In human tissue, tumours with higher macrophage and BDNF levels correlated with poorer survival.

That matters because it anchors mouse mechanism to human outcome. A mechanism demonstrated in mice and absent from human data is a hypothesis; one where the same molecules track with survival in patients is considerably more likely to be operating in the disease as it actually occurs.

The intervention

In mouse studies, blocking BDNF signalling prevented nerves from growing into tumours and significantly reduced tumour growth. An existing marketed drug that blocks BDNF signalling showed promise.

“First, we block LOX…” — no; here the point is simpler. “It looks really promising that we can use this drug, which is already on the market, to target BDNF,” Cox said.

An approved drug shortcuts a great deal. Safety, pharmacokinetics and manufacturing are established, and a repurposing trial can begin without the years of development a novel molecule requires.

The obvious caution about blocking BDNF

BDNF is not an incidental molecule. It is central to neuronal survival, growth and plasticity throughout the nervous system, and it is heavily implicated in learning, memory and mood regulation — reduced BDNF signalling has been associated with depression, and several antidepressants appear to increase it.

Blocking it systemically for cancer treatment therefore raises questions about effects on the nervous system that a mouse tumour study is not designed to detect. Any repurposing programme would need to characterise cognitive and mood effects carefully, and the fact that a marketed drug blocking this signalling already exists implies those effects are at least tolerable in its current indication.

Why triple-negative breast cancer

TNBC has fewer targeted treatment options than other subtypes, because it lacks the hormone receptors and HER2 that provide targets elsewhere. Chemotherapy remains the backbone, and patients who progress have limited alternatives.

Any newly identified mechanism in this subtype attracts attention for that reason, and one with an approved drug attached attracts more.

What this is

Repurposing an approved drug against a newly understood mechanism — tumour-nerve crosstalk — is an appealing shortcut, and these results are preclinical and would need human testing.

Cancer neuroscience as an emerging field

This finding belongs to a line of work that has grown substantially over the past decade and is worth placing.

The relationship between tumours and nerves was long treated as one-directional and largely clinical — nerves as structures cancer invades, producing pain, rather than as participants. Perineural invasion was documented as a prognostic finding without much attention to why it mattered mechanistically.

That has changed with evidence that nerves actively promote tumour growth across several cancers. Work in prostate, gastric and pancreatic cancer has shown that surgically or chemically removing nerve input slows tumour progression, and that tumours actively recruit nerve growth rather than passively encountering it.

The therapeutic implication is unusual, because the drugs that modulate nerve function — beta-blockers, botulinum toxin, agents affecting neurotrophin signalling — are largely old and cheap. A field where the newly identified targets already have approved drugs against them is rare in oncology, and it is why cancer neuroscience findings tend to be accompanied by repurposing proposals.

The broader significance is conceptual. Cancer research has spent decades on the tumour’s interactions with blood vessels and the immune system. Its relationship with the nervous system is a comparatively recent line of investigation, and findings like this suggest it has been an underexamined participant rather than a bystander. Early-stage research; not medical advice.